Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
26 hedge funds and large institutions have $22M invested in Argos Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
24% more funds holding
Funds holding: 21 → 26 (+5)
31% less capital invested
Capital invested by funds: $31.8M → $22M (-$9.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$922K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$154K |
| 3 |
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
|
+$89.2K |
| 4 |
PSI
Pinnacle Summer Investments
Fairfax,
Virginia
|
+$86.6K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$67.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSA
Wall Street Associates
Lajolla,
California
|
-$1.18M |
| 2 |
TAF
Tredje AP-fonden
Se-111 91 Stockholm,
Sweden
|
-$1M |
| 3 |
AIC
AWM Investment Company
New York
|
-$182K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$23K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.13K |
ARGS Hedge Fund Activity: Q3 2015 in Review
26 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q3 2015, worth a combined $22M — down 31% from $31.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ARGS positions and 1 closed out — a net gain of 5 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $922K. The largest seller was Wall Street Associates, cutting an estimated $1.18M.
- 26 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q3 2015, up from 21 in Q2 2015.
- Funds reported $22M of Argos Therapeutics, Inc. stock for Q3 2015, down 31% quarter-over-quarter.
- 6 funds opened new Argos Therapeutics, Inc. positions in Q3 2015 and 1 closed out, a net change of +5 holders.
- The largest Argos Therapeutics, Inc. buyer in Q3 2015 was Wasatch Advisors, an estimated $922K added.
- The largest Argos Therapeutics, Inc. seller in Q3 2015 was Wall Street Associates, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2015.